Merck wins 1st FDA approval for Keytruda
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
GlobalData on MSN5d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravirGilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world.
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...
Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...
Kremlin says Lebanon pager blasts risk igniting tensions in 'explosive' region Merck, a leading science and technology company, launched the first single-use reactor specifically designed to ...
The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' ...
Merck and Siemens have signed a strategic partnership to accelerate digital transformation in manufacturing through smart, ...
The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...
Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback